Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab non-inferiority study versus mepolizumab or benralizumab in severe eosinophilic asthma
NL-OMON60960Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of depemokimab in eosinophilic asthma (EA) (2 arms), sponsored by GSK. Primary endpoint: Annualized rate of clinically significant exacerbations over 52 weeks. Started Apr 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON60960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60960.